Exploiting APC function as a novel cancer therapy

AC Lesko, KH Goss, JR Prosperi - Current drug targets, 2014 - ingentaconnect.com
AC Lesko, KH Goss, JR Prosperi
Current drug targets, 2014ingentaconnect.com
The Adenomatous Polyposis Coli (APC) tumor suppressor is most commonly mutated in
colorectal cancers such as familial adenomatous polyposis (FAP); as well as many other
epithelial cancers like breast, pancreatic, and lung cancer. APC mutations usually result in a
truncated form of the protein lacking the carboxy-terminal region resulting in loss of function.
Mutations in APC have been identified in early stages of cancer development making it a
gatekeeper of tumor progression and therefore an ideal therapeutic target. APC is best …
The Adenomatous Polyposis Coli (APC) tumor suppressor is most commonly mutated in colorectal cancers such as familial adenomatous polyposis (FAP); as well as many other epithelial cancers like breast, pancreatic, and lung cancer. APC mutations usually result in a truncated form of the protein lacking the carboxy-terminal region resulting in loss of function. Mutations in APC have been identified in early stages of cancer development making it a gatekeeper of tumor progression and therefore an ideal therapeutic target. APC is best known for its role as a negative regulator of the Wnt/β -catenin pathway. However, APC also mediates several other normal cell functions independently of Wnt/β-catenin signaling such as apical-basal polarity, microtubule networks, cell cycle, DNA replication and repair, apoptosis, and cell migration. Given the vast cellular processes involving APC, the loss of these
ingentaconnect.com